The platform seems expensive to implement; is it cost-effective compared to traditional omics-based diagnostics, especially for smaller clinics or labs?

The elive Test is designed for affordability and clinical scalability. In contrast to traditional multi-omic assays that rely on deep sequencing and complex bioinformatics, Elephas provides functional, actionable insights to help identify patients most likely to respond to immunotherapy, reducing unnecessary toxicity and treatment costs. The platform uses a standard core needle biopsy (CNB), the most common procedure for cancer diagnosis, and requires no additional infrastructure at the clinical site. All testing and analysis are done in a centralized, CLIA-certified Elephas lab, ensuring consistency, quality, and quick turnaround.